

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for the shares in Alibaba Health Information Technology Limited.



ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED

阿里健康信息技術有限公司

(Incorporated in Bermuda with limited liability)

(Stock Code: 241)

GRANT OF RESTRICTED SHARE UNITS

GRANT OF RESTRICTED SHARE UNITS

On March 15, 2023, the Company granted 360,000 RSUs to eight Grantees in accordance with the terms of the Share Award Scheme, subject to acceptance.

This announcement is made pursuant to Rules 17.06A, 17.06B and 17.06C of the Listing Rules.

RESTRICTED SHARE UNITS

On March 15, 2023, the Company granted 360,000 RSUs to eight Grantees in accordance with the terms of the Share Award Scheme, subject to acceptance. Details of the grant of the RSUs are as follows:

Date of Grant: March 15, 2023

Grantees: Eight employees of the Group, being eligible participants pursuant to the Share Award Scheme

Number of RSUs granted: 360,000

Each of the RSUs granted to the Grantees represents a right to receive a Share on the date the RSU vests.

Consideration for the grant of RSUs:	Nil
Closing price of the Shares on the Date of Grant:	HK\$5.67 per Share
Vesting period:	The RSUs granted shall be vested over one to four years from the Date of Grant
Performance targets:	The RSUs granted are not subject to performance targets
Clawback mechanism:	In the event that any circumstances as specified in the respective grant letter arise, any RSUs granted but unvested will automatically lapse and not be exercisable in respect of the underlying Shares with effect upon the occurrence of the relevant circumstances

In relation to the 360,000 RSUs granted to the Grantees, new Shares that rank *pari passu* in all respects among themselves and with all the Shares in issue from time to time shall be issued and/or existing Shares in issue to be purchased from the market out of cash contributed by the Company and held on trust for the Grantees shall be transferred to the Grantees (as the case may be) upon vesting and settlement of such RSUs.

REASONS FOR AND BENEFITS OF THE GRANTS

The purpose of the aforesaid grant of the RSUs is to (i) attract skilled and experienced personnel for the further development and expansion of the Group by providing them with the opportunity to acquire equity interests in the Company, (ii) recognize the contribution to the success and development of the Group made by the existing employees of Company or its affiliate(s), and/or (iii) generally incentivize and motivate our employees to remain with, and to strive for the future development and expansion of, the Group.

LISTING RULES IMPLICATIONS

To the best of the knowledge of the Directors having made all reasonable enquiries, as at the Date of Grant, (i) none of the Grantees is a Director, chief executive or substantial shareholder of the Company or an associate (as defined under the Listing Rules) of any of them; (ii) none of the Grantees is a participant with options and RSUs granted and to be granted exceeding the 1% individual limit under Rule 17.03D(1) of the Listing Rules; (iii) none of the Grantees is a related entity participant or a service provider (as defined under the Listing Rules); and (iv) no financial assistance has been provided by the Group to the Grantees for the purchase of Shares under the Share Award Scheme.

NUMBER OF SHARES AVAILABLE FOR FUTURE GRANT

Upon the aforesaid grant of the RSUs, 399,030,299 Shares underlying the RSUs may be granted under the Share Award Scheme in the future.

The Share Award Scheme was adopted before the effective date of the new Chapter 17 of the Listing Rules. The Company will comply with the new Chapter 17 in accordance with the transitional arrangements for the existing share scheme.

DEFINITIONS

“Board”	the board of directors of the Company
“Company”	Alibaba Health Information Technology Limited (阿里健康信息技術有限公司), a company incorporated in Bermuda, the shares of which are listed on the Main Board of the Stock Exchange (stock code: 241)
“connected person”	has the same meaning ascribed to it under the Listing Rules
“Date of Grant”	March 15, 2023
“Director(s)”	director(s) of the Company
“Grantees”	employees of the Company or its affiliate(s) who are granted RSUs in accordance with the Share Award Scheme on the Date of Grant
“Group”	the Company and its subsidiaries
“HK\$”	Hong Kong dollars, the lawful currency of Hong Kong
“Hong Kong”	Hong Kong Special Administrative Region of the People’s Republic of China
“Listing Rules”	Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited
“RSU(s)”	restricted share unit(s), being a contingent right to receive Share(s) which is/are awarded under the Share Award Scheme
“Share Award Scheme”	the share award scheme adopted by the Company at a special general meeting on November 24, 2014, the principal terms of which were set out on pages 10 to 20 of the Company’s circular dated October 31, 2014
“Shares”	ordinary shares of HK\$0.01 each in the issued capital of the Company

“Stock Exchange” The Stock Exchange of Hong Kong Limited
“subsidiary” has the same meaning ascribed to it under the Listing Rules

By Order of the Board
Alibaba Health Information Technology Limited
ZHU Shunyan
Chairman and Chief Executive Officer

Hong Kong, March 15, 2023

As at the date of this announcement, the Board comprises Mr. Zhu Shunyan, Mr. Shen Difan and Mr. Tu Yanwu as the executive Directors; Mr. Li Faguang as the non-executive Director; and Mr. Luo Tong, Mr. Wong King On, Samuel and Ms. Huang Yi Fei (Vanessa) as the independent non-executive Directors.